X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Abbott India with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ABBOTT INDIA vs STERLING BIOTECH - Comparison Results

ABBOTT INDIA    Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ABBOTT INDIA STERLING BIOTECH ABBOTT INDIA/
STERLING BIOTECH
 
P/E (TTM) x 37.2 -0.4 - View Chart
P/BV x 9.6 0.0 67,205.7% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 ABBOTT INDIA   STERLING BIOTECH
EQUITY SHARE DATA
    ABBOTT INDIA
Mar-18
STERLING BIOTECH
Dec-13
ABBOTT INDIA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs6,11011 58,190.5%   
Low Rs3,9963 117,529.4%   
Sales per share (Unadj.) Rs1,552.226.8 5,790.5%  
Earnings per share (Unadj.) Rs188.8-15.0 -1,262.3%  
Cash flow per share (Unadj.) Rs196.4-5.5 -3,595.7%  
Dividends per share (Unadj.) Rs55.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs796.654.9 1,451.5%  
Shares outstanding (eoy) m21.25267.87 7.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.30.3 1,255.6%   
Avg P/E ratio x26.8-0.5 -5,759.6%  
P/CF ratio (eoy) x25.7-1.3 -2,022.0%  
Price / Book Value ratio x6.30.1 5,009.1%  
Dividend payout %29.10-   
Avg Mkt Cap Rs m107,3761,862 5,767.7%   
No. of employees `0003.31.4 245.3%   
Total wages/salary Rs m3,937547 720.0%   
Avg. sales/employee Rs Th9,929.35,303.3 187.2%   
Avg. wages/employee Rs Th1,185.1403.8 293.5%   
Avg. net profit/employee Rs Th1,207.7-2,959.0 -40.8%   
INCOME DATA
Net Sales Rs m32,9857,181 459.4%  
Other income Rs m1,17043 2,746.2%   
Total revenues Rs m34,1557,223 472.8%   
Gross profit Rs m5,245947 553.9%  
Depreciation Rs m1622,543 6.4%   
Interest Rs m384,377 0.9%   
Profit before tax Rs m6,215-5,931 -104.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,203-1,924 -114.5%   
Profit after tax Rs m4,012-4,007 -100.1%  
Gross profit margin %15.913.2 120.6%  
Effective tax rate %35.432.4 109.2%   
Net profit margin %12.2-55.8 -21.8%  
BALANCE SHEET DATA
Current assets Rs m22,65514,335 158.0%   
Current liabilities Rs m6,68149,809 13.4%   
Net working cap to sales %48.4-494.0 -9.8%  
Current ratio x3.40.3 1,178.3%  
Inventory Days Days65403 16.1%  
Debtors Days Days29171 17.1%  
Net fixed assets Rs m83555,432 1.5%   
Share capital Rs m213268 79.3%   
"Free" reserves Rs m16,71513,935 119.9%   
Net worth Rs m16,92814,701 115.1%   
Long term debt Rs m09,478 0.0%   
Total assets Rs m24,16273,988 32.7%  
Interest coverage x163.7-0.4 -46,115.2%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x1.40.1 1,406.6%   
Return on assets %16.80.5 3,346.7%  
Return on equity %23.7-27.3 -87.0%  
Return on capital %36.9-6.4 -574.9%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m3691,860 19.8%   
Fx outflow Rs m3,80725 15,293.6%   
Net fx Rs m-3,4381,835 -187.4%   
CASH FLOW
From Operations Rs m1,5271,719 88.8%  
From Investments Rs m-2,148-3,148 68.2%  
From Financial Activity Rs m-1,0241,426 -71.8%  
Net Cashflow Rs m-1,646-3 48,400.0%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 7.9 0.0 -  
FIIs % 0.1 9.9 1.0%  
ADR/GDR % 0.0 16.9 -  
Free float % 17.1 39.3 43.5%  
Shareholders   18,270 21,482 85.0%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ABBOTT INDIA With:   ALEMBIC LTD  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SUN PHARMA  

Compare ABBOTT INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Brexit Deal; Key Q2FY19 Results & Top Stocks in Focus Today(Pre-Open)

On Thursday, Indian share markets ended marginally higher led by bank stocks and finance stocks. At the closing bell, the BSE Sensex ended up by 119 points.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (2QFY19); Net Profit Up 0.1% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, ABBOTT INDIA has posted a net profit of Rs 1 bn (up 0.1% YoY). Sales on the other hand came in at Rs 10 bn (up 5.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

Which Equity Mutual Funds to Buy Now?(Outside View)

Nov 13, 2018

PersonalFN explains that in falling markets investing in equity mutual funds can be beneficial in long run by choosing the right equity mutual fund scheme.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ABBOTT INDIA SHARE PRICE


Nov 15, 2018 (Close)

TRACK ABBOTT INDIA

  • Track your investment in ABBOTT INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ABBOTT INDIA 8-QTR ANALYSIS

COMPARE ABBOTT INDIA WITH

MARKET STATS